Oil rebounds, Gold is up, and a $500 billion US aid package is on the way

Published 24-APR-2020 09:40 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Markets were mixed on Thursday as investors weighed a rebound in oil prices and prospects for further government stimulus against stark economic data showing the toll of the coronavirus pandemic.

In the US, the S&P 500 started out strong only to close slightly lower, down 0.05% at 2797.8, the Nasdaq Composite slipped 0.01% to 8494.75, while the Dow Jones gained 0.17% to end the day at 23,515.26.

Weighing on the market was news that Gilead Science has terminated a Chinese study after results showed that its remdesivir did not improve COVID-19 patients' condition or reduce the pathogen's presence in the bloodstream.

The market was encouraged a week ago by a report that COVID-19 patients had responded positively to remdesivir in a separate study.

Another 4.4 million people filed for unemployment benefits in the week to 18 April, bringing the total US jobless claims figure to more than 26 million since the pandemic began. This translates roughly to a 15% unemployment rate.

After the market close, US Congress delivered a nearly $US500 billion aid package to support small businesses and hospitals that have struggled amidst the coronavirus pandemic.

The manufacturing and service sectors could also use some help, with the flash service PMI falling to record lows and the manufacturing PMI dropping to its lowest level in 11 years as business activity has slumped due to the lockdowns to combat the coronavirus pandemic.

US coronavirus deaths topped 49,000 on Thursday as the number of lives lost in April rises by an average of 2,000 a day, according to a Reuters tally. At that rate, US deaths will reach 50,000 no later than Friday.

The total number of US cases was approaching 860,000 with many states yet to report on Thursday.

This compares with 75 deaths and close to 7,000 cases in Australia, while the global toll has reached nearly 189,000 deaths and 2.7 million cases.

European markets showed some strength with the FTSE 100 gaining 55.98 points to close up 0.97% at 5826 points.

The DAX was up 0.95% to 10,513 points, while the CAC 40 gained 0.89% pushing it to a close of 4451.

Spot gold added 1.0% to $1,730.50 an ounce. U.S. gold futures gained 0.73% to $1,733.30 an ounce as supplies tighten amid rising concerns over the longer-term economic impact of the pandemic.

Oil prices were higher with Brent crude gaining 8.4% to $US22.09 per barrel and U.S. Oil gained 27.2% to $US17.53 per barrel.

Iron ore was weaker, down 0.7% to $US84.46 per tonne.

The local market yesterday

The benchmark S&P/ASX 200 (ASX:XJO) ended the day yesterday down 4.1 points, or 0.1%, to 5217.1. The index had been up more than 1% earlier in the day before healthcare and bank stocks dragged on the index, locking in the fourth day of losses.

All four of the big banks ended the day lower, while in healthcare CSL lost 2% to $306.67, Cochlear slid by 1.4% to $179.34 and Ramsay Healthcare slumped 5.9% after a capital raising.

The ASX SPI200 suggests the market will open higher 12 points this morning at 5206.

Yesterday marked a month since the local market reached its lowest level since 2012 of 4546 on March 23 and there is speculation that it could head back towards those levels.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X